Skip to main content
. 2018 Aug 16;3(5):e000411. doi: 10.1136/esmoopen-2018-000411

Figure 1.

Figure 1

Study design. Bmab, bevacizumab; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; mCRC, metastatic colorectal cancer; q(x)w, once every (x) weeks.